Prescription drugs sales at 340B prices were $38.8 billion in 2020, “more than three times the level of 340B sales compared to just five years prior,” new drug industry funded research shows.
Total sales would have been $93.6 billion if
…
Category: Pharma Industry
Bausch Health this afternoon became the 18th drug manufacturer to impose conditions on 340B pricing when covered entities use contract pharmacies. The restrictions apply to all entities; there is no exemption for federal grantees.
According to Bausch’s announcement, effective Aug.
…
Drug manufacturer UCB says it is reviewing Monday’s letter from the U.S. Health Resources and Services Administration telling the company its restrictions on 340B pricing to covered entities that use contract pharmacies break federal law and must end immediately.
“At
…
Federal healthcare officials told drug manufacturer UCB yesterday its restrictions on 340B pricing when covered entities use contract pharmacies are illegal and must stop or the company could face civil monetary penalties of up to $6,323.00 for each instance of
…
Drug manufacturer Gilead on Wednesday added 45-day time limits for replenishment orders and claims submissions to its conditions on 340B pricing when covered entities use contract pharmacies.
Ten manufacturers require covered entities to provide claims data to industry contractor 340B
…
Growth in 340B covered entities’ use of contract pharmacies to dispense 340B drugs, coupled with growth in pharmacy benefit managers’ control over these pharmacies, has given PBMs an outsized, profit-driven role in the 340B program that does not benefit patients,
…Bipartisan U.S. House Group Renewing Pressure on HHS to Punish Drug Makers Over 340B Pricing Denials
Six U.S. House members—three Democrats and three Republicans—are urging fellow representatives to sign a letter asking U.S. Health and Human Services (HHS) Department leaders “to begin enforcement actions against pharmaceutical companies that refuse to honor 340B discounts on prescription drugs.”
…
The National Association of Community Health Centers this week strongly urged drug manufacturer Merck to eliminate “all conditions imposed on health centers to receive 340B price drugs at contract pharmacies.”
Merck’s April 28 decision to extend its restrictions on 340B pricing
…
Drug manufacturers Novartis and United Therapeutics (UT) last night urged a federal appeals court in Washington, D.C., to affirm a lower court’s November 2021 judgement that the 340B statute does not stop manufacturers from attaching any conditions to 340B drug
…
Biopharmaceutical manufacturer Exelixis yesterday became the 17th drug maker to impose conditions on 340B pricing when hospitals use contract pharmacies.
The company, a specialty manufacturer with two high-priced drug products on the market, announced its policy in email notices to covered
…